Wegener's granulomatosis (newly renamed granulomatosis with polyangiitis [WG/GPA]) is a granulomatous autoimmune inflammatory disorder of unknown etiology that is associated with anti-neutrophil ...

Urticaria affects both children and adults, with chronic cases more common in women, and often presents in emergency or dermatology settings. Conditions like vasculitic urticaria, erythema ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Urticaria, commonly known as hives, is a skin condition that manifests as itchy welts or raised patches on the skin. These welts can vary in size and often change shape or location, making the ...

According to GlobalData, Phase II drugs for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis ... chronic spontaneous urticaria, severe uncontrolled asthma, eosinophilic granulomatosis with ...

Orofacial granulomatosis is a rare skin condition that causes swelling in the face, mouth, or lips. The cause is often unknown, but experts think it’s related to allergies or an immune reaction.

The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Study participants were ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: "This approval is ...

Approval was based on results from the MANDARA Phase III trial, which demonstrated the superiority of Fansenra over Nucala in patients with eosinophilic granulomatosis with ... issues with breathing, ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). The FDA has approved an expanded indication of AstraZeneca’s benralizumab ...

Please provide your email address to receive an email when new articles are posted on . The safety of benralizumab showed no “meaningful difference” compared with mepolizumab. Benralizumab ...